Abstract
Subgroup analyses in clinical trials sometimes reveal gender-/sex-dependent differences in cancer outcomes. However, drug approvals are rarely restricted to a specific sex or gender, and recommendations regarding dosage are rarely tailored accordingly. Furthermore, discrepancies exist between the gender-/sex-dependent enrollment rates in clinical trials and real-world incidence or mortality rates. This article highlights gender-/sex differences in clinical trials in uro-oncology.
Translated title of the contribution | Gender-/Sex-Specific Differences in Clinical Trials in Uro-Oncology |
---|---|
Original language | German |
Journal | Aktuelle Urologie |
Volume | 56 |
Issue number | 2 |
Pages (from-to) | 131-134 |
Number of pages | 4 |
ISSN | 0001-7868 |
DOIs | |
Publication status | Published - 28.01.2025 |
Research Areas and Centers
- Research Area: Luebeck Integrated Oncology Network (LION)
DFG Research Classification Scheme
- 2.22-23 Reproductive Medicine, Urology
- 2.22-14 Hematology, Oncology